Windtree Therapeutics sells Seismic IP and related assets to Seismic Operations for USD 150,000
WINT•Windtree agrees to sell cardiovascular program assets
Windtree Therapeutics agreed to sell Seismic Pharmaceuticals’ cardiovascular program assets to Seismic Pharmaceuticals Operations in an asset purchase agreement dated Dec. 16, 2025.
- Upfront consideration totals USD 150,000 cash at closing.
- Windtree can receive USD 700,000 if the buyer completes a post-closing financing of at least USD 10 million.
- Windtree is also entitled to 20% of certain license-out economics tied to the transferred intellectual property, with a USD 1.2 million buyout option following a qualifying financing.
- The deal includes a planned transfer of control of a Taiwanese subsidiary effective no earlier than Jan. 1, 2026.
